June 2025, Vol 2, No 6
The historic utilization of gene editing CRISPR technology to treat a baby boy with a rare, incurable condition known as carbamoyl phosphate synthetase 1 (CPS1) deficiency represents a turning point in medicine, opening the possibility of personalized treatments in all parts of the body. Read More ›
More than 20% of Iraq and Afghanistan war veterans are reportedly suffering from post-traumatic stress disorder (PTSD), and more than 450,000 service members have been diagnosed with at least 1 traumatic brain injury over the past 20 years. Read More ›
Immune checkpoint inhibitors (ICIs) have altered the management of several cancers, including a subset of colorectal cancers (CRCs) characterized by deficient mismatch repair (dMMR) and microsatellite instability (MSI). Read More ›
The FDA has approved penpulimab-kcqx (Akeso Biopharma Co, Ltd) with cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC) and as a single agent for adults with metastatic non-keratinizing NPC with disease progression on or after platinum-based chemotherapy and at least 1 other previous line of therapy. Read More ›
Officials with the FDA have approved nivolumab (Opdivo; Bristol Myers Squibb) with ipilimumab (Yervoy; Bristol Myers Squibb) for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC). Read More ›
Nivolumab (Opdivo; Bristol Myers Squibb) with ipilimumab (Yervoy; Bristol Myers Squibb) is now FDA approved for patients aged ≥12 years with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair–deficient (dMMR) colorectal cancer (CRC). Read More ›
Officials with the FDA have approved tislelizumab-jsgr (Tevimbra; BeOne Medicines, Ltd, formerly known as BeiGene, Ltd), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express programmed death-ligand 1 (PD-L1) (≥1). Read More ›
As the number of confirmed measles cases continues to climb here in the United States, officials with TRICARE are reminding people that the “best defense against measles is getting vaccinated.” Read More ›
Getting healthcare overseas doesn’t have to be difficult, as TRICARE officials noted that they offer a program to help. Read More ›
The Department of Veterans Affairs (VA) recently announced that they will be moving the VA’s Office of Survivors Assistance from the Veterans Benefits Administration to the Office of the VA Secretary, and are actively looking to identify areas where automation can be used to expedite Dependency and Indemnity Compensation (DIC) claims. Read More ›